BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23076450)

  • 1. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
    Littlejohn TW; Jones SW; Zhang J; Hsu H; Keefe DL
    J Hum Hypertens; 2013 May; 27(5):321-7. PubMed ID: 23076450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
    Lacourcière Y; Taddei S; Konis G; Fang H; Severin T; Zhang J
    J Hypertens; 2012 Oct; 30(10):2047-55. PubMed ID: 22828090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with stage 2 hypertension.
    Ferdinand KC; Weitzman R; Purkayastha D; Sridharan K; Jaimes EA
    J Am Soc Hypertens; 2012; 6(3):219-27. PubMed ID: 22305998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥.
    Pfeiffer D; Rennie N; Papst CC; Zhang J
    Curr Vasc Pharmacol; 2012 Nov; 10(6):773-80. PubMed ID: 22303911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy.
    Glorioso N; Thomas M; Troffa C; Argiolas G; Patel S; Baek I; Zhang J
    Curr Vasc Pharmacol; 2012 Nov; 10(6):748-55. PubMed ID: 22303910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
    Townsend RR; Forker AD; Bhosekar V; Yadao A; Keefe DL
    J Clin Hypertens (Greenwich); 2011 Dec; 13(12):889-97. PubMed ID: 22142348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
    Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial.
    Braun-Dullaeus RC; Shustov SB; Alvarez C; Rogelio GG; Zhang J; Hristoskova S; Häring DA
    Int J Clin Pract; 2012 Sep; 66(9):834-42. PubMed ID: 22897460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.